Insider Selling: CeriBell (NASDAQ:CBLL) CFO Sells $36,534.42 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 1,521 shares of CeriBell stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $24.02, for a total transaction of $36,534.42. Following the completion of the sale, the chief financial officer directly owned 146,600 shares in the company, valued at approximately $3,521,332. This represents a 1.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scott Blumberg also recently made the following trade(s):

• On Wednesday, August 19th, Scott Blumberg sold 33,512 shares of CeriBell stock. The shares were sold at an average price of $25.03, for a total value of $838,805.36.
• On Tuesday, August 18th, Scott Blumberg sold 990 shares of CeriBell stock. The shares were sold at an average price of $25.00, for a total value of $24,750.00.

CeriBell Stock Down 0.3%

CBLL stock opened at $23.37 on Friday. The stock has a fifty day moving average of $20.00 and a 200-day moving average of $19.32. CeriBell, Inc. has a fifty-two week low of $10.85 and a fifty-two week high of $25.33. The company has a market capitalization of $896.94 million, a price-to-earnings ratio of -13.28 and a beta of 0.81. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The firm had revenue of $28.10 million during the quarter, compared to the consensus estimate of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. As a group, equities research analysts predict that CeriBell, Inc. will post -1.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on CBLL. Canaccord Genuity Group upped their price target on shares of CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Barclays raised shares of CeriBell to a “neutral” rating in a report on Tuesday, August 18th. Finally, BTIG Research raised their price target on CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, CeriBell presently has an average rating of “Moderate Buy” and a consensus target price of $22.40.

Institutional Investors Weigh In On CeriBell

Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of CeriBell in the second quarter valued at approximately $37,657,000. Bank of New York Mellon Corp lifted its stake in CeriBell by 1,945.9% in the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock worth $26,797,000 after purchasing an additional 1,162,200 shares in the last quarter. KCM Capital Inc purchased a new stake in CeriBell in the 4th quarter worth approximately $21,930,000. TimesSquare Capital Management LLC bought a new position in CeriBell in the 2nd quarter valued at $15,182,000. Finally, Royce & Associates LP purchased a new position in shares of CeriBell during the 4th quarter valued at $11,695,000.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.